keyword
MENU ▼
Read by QxMD icon Read
search

Biochemical relapse of prostate cancer

keyword
https://www.readbyqxmd.com/read/28417160/diagnosis-of-recurrent-prostate-cancer-with-pet-ct-imaging-using-the-gastrin-releasing-peptide-receptor-antagonist-68-ga-rm2-preliminary-results-in-patients-with-negative-or-inconclusive-18-f-fluoroethylcholine-pet-ct
#1
Gesche Wieser, Ilinca Popp, H Christian Rischke, Vanessa Drendel, Anca-Ligia Grosu, Mark Bartholomä, Wolfgang A Weber, Rosalba Mansi, Ulrich Wetterauer, Wolfgang Schultze-Seemann, Philipp T Meyer, Cordula Annette Jilg
PURPOSE/BACKGROUND: [(18)F]fluoroethylcholine ((18)FECH) has been shown to be a valuable PET-tracer in recurrent prostate cancer (PCa), but still has limited accuracy. RM2 is a gastrin-releasing peptide receptor (GRPr) antagonist that binds to GRPr on PCa cells. Recent studies suggest that GRPr imaging with PET/CT is a promising technique for staging and restaging of PCa. We explore the value of GRPr-PET using the (68)Ga-labeled GRPr antagonist RM2 in a selected population of patients with biochemically recurrent PCa and a negative/inconclusive (18)FECH-PET/CT...
April 18, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28413378/is-age-an-independent-factor-for-prostate-cancer-a-paired-analysis
#2
José Arnaldo Shiomi da Cruz, Carlo C Passerotti, Sabrina Thalita Dos Reis, Mary Ellen Salles Guariero, Olimpio Daniel de Campos, Katia Ramos Moreira Leite, Miguel Srougi
INTRODUCTION: Prostate cancer is the most prevalent malignant neoplasia among men worldwide. Several prognostic factors, including Gleason's score, the measurement of serum prostate-specific antigen (PSA) and the evaluation of the percentage of fragments affected by cancer on prostate biopsy, have already been established. Age alone, however, has yet to be studied as a prognostic factor independently from other known factors. The aim of the present study was to compare the characteristics and the evolution of prostate cancer in different age groups using a paired analysis for patients with equivalent known prognostic factors...
January 2017: Current Urology
https://www.readbyqxmd.com/read/28399576/local-tumor-control-and-dna-pk-activity-of-peripheral-blood-lymphocytes-in-prostate-cancer-patients-receiving-radiotherapy
#3
Masanori Someya, Tomokazu Hasegawa, Masakazu Hori, Yoshihisa Matsumoto, Kensei Nakata, Naoya Masumori, Koh-Ichi Sakata
Repair of DNA damage is critical for genomic stability, and DNA-dependent protein kinase (DNA-PK) has an important role in repairing double-strand breaks. We examined whether the DNA-PK activity of peripheral blood lymphocytes (PBLs) was related to biochemical (prostate-specific antigen: PSA) relapse and radiation toxicity in prostate cancer patients who have received radiotherapy. A total of 69 patients with localized adenocarcinoma of the prostate participated in this study. Peripheral blood was collected 2 years or later after radiotherapy and centrifuged, then DNA-PK activity was measured by a filter binding assay...
March 1, 2017: Journal of Radiation Research
https://www.readbyqxmd.com/read/28397507/-stereotactic-body-radiotherapy-of-prostate-cancer-effectiveness-and-toxicity
#4
E Skácelíková, D Feltl, J Cvek, T Jelenová, L Knybel, H Tomášková
BACKGROUND: Prostate cancer is the most prevalent cancer in males and its incidence is steadily increasing. Most cases of prostate cancer are diagnosed during the early asymptomatic period, in which case the prognosis is very good. Therapies differ widely in their efficacies and toxicities, and this is an important consideration when it comes to deciding which treatment is optimal for a particular patient. One treatment method for early stage prostate cancer is stereotactic body radiotherapy (SBRT)...
2017: Klinická Onkologie: Casopis Ceské a Slovenské Onkologické Spolecnosti
https://www.readbyqxmd.com/read/28396223/oncological-and-functional-results-of-robotic-salvage-radical-prostatectomy-after-permanent-brachytherapy-implants
#5
M Orré, T Piéchaud, P Sargos, P Richaud, G Roubaud, L Thomas
PURPOSE: To evaluate the feasibility of robotic salvage prostatectomy for local recurrence after permanent brachytherapy implants for prostate cancer. PATIENTS AND METHODS: Seven patients were operated by robotic salvage prostatectomy with or without pelvic lymph node dissection between October 2007 and March 2012, for a local recurrence after iodine 125 permanent brachytherapy implants. Local recurrence was proved by prostate biopsies, once biochemical relapse was diagnosed and imaging assessment performed...
April 7, 2017: Cancer Radiothérapie: Journal de la Société Française de Radiothérapie Oncologique
https://www.readbyqxmd.com/read/28379896/spectrum-of-metastatic-and-nonmetastatic-skeletal-findings-with-dual-phase-18f-fech-pet-ct-in-patients-with-biochemical-relapse-of-prostate-cancer
#6
Athar Haroon, Rizwan Syed, Raymond Endozo, Rayjanah Allie, Alex Freeman, Mark Emberton, Jamshed Bomanji
INTRODUCTION: The aim of this study was to evaluate the spectrum of skeletal findings on dual-phase fluorine-18-fluoroethylcholine (F-FECH) PET/CT performed during the work-up of patients referred for suspected prostate cancer relapse. MATERIALS AND METHODS: Three hundred F-FECH PET/CT scans were evaluated prospectively. The low-dose CT features of all cases were categorized as isodense, sclerotic, lytic or mixed lytic/sclerotic and maximum standardized uptake value (SUVmax) values were calculated...
May 2017: Nuclear Medicine Communications
https://www.readbyqxmd.com/read/28376164/germline-mutations-in-the-kallikrein-6-region-and-predisposition-for-aggressive-prostate-cancer
#7
Laurent Briollais, Hilmi Ozcelik, Jingxiong Xu, Maciej Kwiatkowski, Emilie Lalonde, Dorota H Sendorek, Neil E Fleshner, Franz Recker, Cynthia Kuk, Ekaterina Olkhov-Mitsel, Tristan Juvet, Ioannis Prassas, John Trachtenberg, Ants Toi, Michael Fraser, Theodorus van der Kwast, Robert G Bristow, Bharati Bapat, Eleftherios P Diamandis, Paul C Boutros, Alexandre R Zlotta
Background: There is a need for markers that can specifically identify individuals at increased risk of harboring aggressive forms of prostate cancer (PCa). Methods: We surveyed the Kallikrein ( KLK ) region ( KLK 1-15) for single-nucleotide polymorphisms (SNPs) associated with aggressive PCa (Gleason Score ≥ 8) in 1858 PCa patients. Discovery cohorts (Swiss arm of the European Randomized Study of Screening for PCa, n = 379; Toronto, Canada, n = 540) and a validation cohort (Prostate, Lung, Colorectal and Ovarian [PLCO] screening trial, n = 939) were analyzed...
April 1, 2017: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/28371244/predictive-value-of-the-2014-international-society-of-urological-pathology-grading-system-for-prostate-cancer-in-radical-prostatectomy-patients-with-long-term-follow-up
#8
Judith Grogan, Ruta Gupta, Kate L Mahon, Phillip D Stricker, Anne-Maree Haynes, Warick Delprado, Jennifer Turner, Lisa G Horvath, James G Kench
OBJECTIVE: To assess the relationship between the ISUP 2014 grading system, biochemical relapse (BCR) and clinical relapse (CLR) following radical prostatectomy, to determine whether the 2014 ISUP grading system is a better predictor of survival compared to the previous Gleason scoring systems, and to investigate whether incorporation of the tertiary pattern/grade into the ISUP scoring system significantly improves its efficacy. PATIENTS AND METHODS: 635 radical prostatectomy cases (1991-1999) were identified from a database at a single institution...
March 28, 2017: BJU International
https://www.readbyqxmd.com/read/28368893/early-detection-of-bilateral-testicular-metastases-from-prostatic-adenocarcinoma-using-68ga-psma-ligand-pet-ct
#9
Desiree Weiberg, Herbert Radner, Thorsten Derlin, Walter F Thon
We present the case of a 76-year-old man with biochemical relapse after primary therapy for prostate cancer. Ga prostate-specific membrane antigen (PSMA) ligand PET/CT performed for localization of recurrent disease revealed bilateral metastases to the testes. Histopathologic evaluation after bilateral orchiectomy revealed testicular metastases. Metastases to the testes are rare and usually seen in advanced stages. Ga-PSMA ligand PET/CT is a highly sensitive and specific imaging method for the detection of primary and metastatic prostate cancer and has refined diagnostic approaches...
March 31, 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/28344597/high-biologically-effective-dose-radiation-therapy-using-brachytherapy-in-combination-with-external-beam-radiotherapy-for-high-risk-prostate-cancer
#10
Keisei Okamoto, Akinori Wada, Naoaki Kohno
PURPOSE: To evaluate the outcomes of high-risk prostate cancer patients treated with biologically effective dose (BED) ≥ 220 Gy of high-dose radiotherapy, using low-dose-rate (LDR) brachytherapy in combination with external beam radiotherapy (EBRT) and short-term androgen deprivation therapy (ADT). MATERIAL AND METHODS: From 2005 to 2013, a total of 143 patients with high-risk prostate cancer were treated by radiotherapy of BED ≥ 220 Gy with a combination of LDR brachytherapy, EBRT, and androgen deprivation therapy (ADT)...
February 2017: Journal of Contemporary Brachytherapy
https://www.readbyqxmd.com/read/28333019/a-comparison-between-low-dose-rate-brachytherapy-with-or-without-androgen-deprivation-external-beam-radiation-therapy-with-or-without-androgen-deprivation-and-radical-prostatectomy-with-or-without-adjuvant-or-salvage-radiation-therapy-for-high-risk-prostate
#11
Jay P Ciezki, Michael Weller, Chandana A Reddy, Jeffrey Kittel, Harguneet Singh, Rahul Tendulkar, Kevin L Stephans, James Ulchaker, Kenneth Angermeier, Andrew Stephenson, Steven Campbell, Georges-Pascal Haber, Eric A Klein
PURPOSE: We compare the efficacy and toxicity among the 3 major modalities available used to treat high-risk prostate cancer (HRCaP). METHODS AND MATERIALS: From 1996 to 2012, 2557 HRCaP patients were treated: 734 received external beam radiation therapy (EBRT) with or without androgen deprivation therapy (ADT), 515 received low-dose-rate prostate brachytherapy (LDR) with or without ADT, and 1308 received radical prostatectomy (RP) with or without EBRT. Biochemical relapse-free survival (bRFS), clinical relapse-free survival (cRFS), and prostate cancer-specific mortality (PCSM) were assessed...
April 1, 2017: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/28317152/-68-ga-psma-pet-for-radiation-treatment-planning-in-prostate-cancer-recurrences-after-surgery-individualized-medicine-or-new-standard-in-salvage-treatment
#12
Gregor Habl, Katharina Sauter, Kilian Schiller, Sabrina Dewes, Tobias Maurer, Matthias Eiber, Stephanie E Combs
BACKGROUND: (68) Ga-PSMA-PET imaging is a novel promising diagnostic tool to locate early biochemical failure after radical prostatectomy (RP) in prostate cancer (PC) patients. Exact knowledge of the relapse location may result in changes of the therapy concept aside from changes to the TNM stage. To gain data for this approach, we evaluated PC patients receiving (68) Ga-PSMA-PET imaging before salvage radiotherapy (RT). METHODS AND MATERIALS: In this study, 100 patients with biochemical failure after RP± prior RT who underwent (68) Ga-PSMA PET/CT or PET/MRI were evaluated undergoing salvage RT in our department...
June 2017: Prostate
https://www.readbyqxmd.com/read/28314292/-68-ga-psma-ligand-pet-ct-based-radiotherapy-for-lymph-node-relapse-of-prostate-cancer-after-primary-therapy-delays-initiation-of-systemic-therapy
#13
Christoph Henkenberens, Christoph A VON Klot, Tobias L Ross, Frank M Bengel, Hans-Jürgen Wester, Hüper Katja, Hans Christiansen, Thorsten Derlin
AIM: To evaluate (68)Ga-PSMA ligand positron-emission tomography-computed tomography (PET/CT)-based radiotherapy for lymph node metastases of prostate cancer after primary therapy. PATIENTS AND METHODS: Twenty-three patients received radiotherapy for PSMA ligand-positive lymph node metastases. RESULTS: The median follow-up time was 12.4 (range=6.0-28.5) months. The median pre-treatment prostate-specific antigen (PSA) decreased from 2.75 (range=0...
March 2017: Anticancer Research
https://www.readbyqxmd.com/read/28280856/comparison-of-standard-and-delayed-imaging-to-improve-the-detection-rate-of-68-ga-psma-i-t-pet-ct-in-patients-with-biochemical-recurrence-or-prostate-specific-antigen-persistence-after-primary-therapy-for-prostate-cancer
#14
Sebastian Schmuck, Stefan Nordlohne, Christoph-A von Klot, Christoph Henkenberens, Jan M Sohns, Hans Christiansen, Hans-Jürgen Wester, Tobias L Ross, Frank M Bengel, Thorsten Derlin
PURPOSE: The aim of this study was to assess the value of dual-time point imaging in PET/CT for detection of biochemically recurrent or persistent prostate cancer, using the prostate-specific membrane antigen (PSMA) ligand [(68)Ga]PSMA I&T. METHODS: 240 patients who underwent a [(68)Ga]PSMA I&T PET/CT in the context of biochemical relapse of prostate cancer were included in this retrospective analysis. Imaging consisted of a standard whole-body PET/CT (1 h p.i.), followed by delayed (3 h p...
March 9, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28278446/fluorocholine-pet-ct-predicts-skeletal-progression-skeletal-event-and-cancer-specific-survival-in-patients-with-biochemical-relapse-for-prostate-cancer
#15
Fabio Zattoni, Emanuela Agostini, Francesco Cattaneo, Marco Maruzzo, Umberto Basso, Filiberto Zattoni, Laura Evangelista
PURPOSE: The aim of our study is to evaluate the prognostic impact of (18)F-Choline (FCh) positron emission tomography (PET)/computed tomography (CT), CT alone and methylene diphophonate bone scan (MDP-BS) in prostate cancer (PCa) patients with biochemical relapse. METHODS: We retrospectively selected 58 patients who underwent, between June 2010 and February 2013, both FCh-PET/CT and MDP-BS within a maximum time interval of 5months. All patients had a biochemical PCa recurrence after radical prostatectomy and/or radiation therapy...
February 24, 2017: Clinical Imaging
https://www.readbyqxmd.com/read/28224113/intensity-modulated-radiation-therapy-with-stereotactic-body-radiation-therapy-boost-for-unfavorable-prostate-cancer-a-report-on-3-year-toxicity
#16
Ima Paydar, Abigail Pepin, Robyn A Cyr, Joseph King, Thomas M Yung, Elizabeth G Bullock, Siyuan Lei, Andrew Satinsky, K William Harter, Simeng Suy, Anatoly Dritschilo, John H Lynch, Thomas P Kole, Sean P Collins
BACKGROUND: Recent data suggest that intensity-modulated radiation therapy (IMRT) plus brachytherapy boost for unfavorable prostate cancer provides improved biochemical relapse-free survival over IMRT alone. Stereotactic body radiation therapy (SBRT) may be a less invasive alternative to brachytherapy boost. Here, we report the 3-year gastrointestinal (GI) and genitourinary (GU) toxicities of IMRT plus SBRT boost. MATERIALS AND METHODS: Between March 2008 and September 2012, patients with prostate cancer were treated with robotic SBRT (19...
2017: Frontiers in Oncology
https://www.readbyqxmd.com/read/28195907/solitary-psma-positive-pulmonary-metastasis-in-biochemical-relapse-of-prostate-cancer
#17
Nils Groe Hokamp, Carsten Kobe, Eric Linzenich, David Maintz, Alexander Drzezga
A 63-year-old man with a history of prostate cancer, treated with resection, radiation, and androgen-depriving therapy over 4 years, was referred to our department with suspicion of recurrence based on increased blood PSA levels (1.60 ng/mL). Ga PSMA PET/CT identified a solitary, PSMA-positive pulmonary nodule in the right lung. After resection, histologic analysis confirmed prostatic origin, and the blood PSA level decreased to 0.13 ng/mL. Solitary pulmonary metastasis from prostate cancer is rare. The benefits of local treatment of a single metastasis even in advanced disease are disputed among oncologists...
May 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/28139422/salvage-of-locally-recurrent-prostate-cancer-after-external-beam-radiation-using-reduced-dose-brachytherapy-with-neoadjuvant-plus-adjuvant-androgen-deprivation
#18
Brian C Baumann, John C Baumann, John P Christodouleas, Edward Soffen
PURPOSE: Local recurrence (LR) of prostate cancer after external beam radiotherapy (EBRT) is a serious problem. Our purpose was to determine if reduced-dose salvage brachytherapy could achieve high rates of biochemical control with acceptable toxicity if combined with androgen deprivation therapy (ADT). METHODS AND MATERIALS: Thirty-three consecutive patients with LR after EBRT were treated with salvage brachytherapy plus ADT from 1998 to 2013. All had pathologically confirmed LR, disease-free interval ≥18 months after EBRT, no distant/nodal metastasis, and International Prostate Symptom Score ≤15...
January 27, 2017: Brachytherapy
https://www.readbyqxmd.com/read/28139024/anatomical-patterns-of-recurrence-following-biochemical-relapse-after-post-prostatectomy-salvage-radiation-therapy-a-multi-institutional-study
#19
William C Jackson, Neil B Desai, Ahmed E Abugharib, Vasu Tumati, Robert T Dess, Jae Y Lee, Shuang G Zhao, Moaaz Soliman, Michael Folkert, Aaron Laine, Raquibul Hannan, Zachary S Zumsteg, Howard Sandler, Daniel A Hamstra, Jeffrey S Montgomery, David C Miller, Mike A Kozminski, Brent K Hollenbeck, Jason W Hearn, Ganesh Palapattu, Scott A Tomlins, Rohit Mehra, Todd M Morgan, Felix Y Feng, Daniel E Spratt
OBJECTIVES: To characterise the frequency and detailed anatomical sites of failure for patients receiving post-radical prostatectomy (RP) salvage radiation therapy (SRT). PATIENTS AND METHODS: A multi-institutional retrospective study was performed on 574 men who underwent SRT between 1986 and 2013. Anatomical recurrence patterns were classified as lymphotrophic (lymph nodes only), osteotrophic (bone only), or multifocal if both were present. Isolated first failure sites were defined as sites of initial clinically detected recurrence that remained isolated for at least 3 months...
January 31, 2017: BJU International
https://www.readbyqxmd.com/read/28134691/parathyroid-adenoma-mimicking-a-malignant-lymph-node-on-18f-choline-pet-ct
#20
Bliede Van den Broeck, Daan De Maeseneer, Ruth De Gersem, Kathia De Man
Prostate carcinoma is the most common cancer in men. After local therapy, disease recurs in many patients. A choline PET/CT is indicated in case of biochemical relapse of prostate carcinoma to determine the site of recurrence (local and/or distant) and to help select the next line of therapy. Choline PET-CT is also known to show an elevated uptake in hyperfunctioning parathyroid adenoma. This case report shows the difficulty to distinguish between both entities if they occur simultaneously in an oncologic patient...
January 27, 2017: Clinical Nuclear Medicine
keyword
keyword
111181
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"